Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II axitinib in advanced angiosarcoma and other soft tissue sarcomas
2008-006007-23Phase 2Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in soft tissue sarcoma (STS), angiosarcoma, leiomyosarcoma (LMS) and 1 more, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival rate at 12 weeks. Started Jul 2009; status: completed.
02
Drugs
axitinib
03
Conditions
soft tissue sarcoma (STS)angiosarcomaleiomyosarcoma (LMS)synovial sarcoma (SS)
Beyond the preview
Go deeper on 2008-006007-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006007-23.